03:03:39 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
BioGaia är verksamma inom bioteknik. Bolaget utvecklar, marknadsför och säljer probiotiska produkter. Produkterna är huvudsakligen baserade på bakterien lactobacillus reuteri som har probiotiska effekter. Idag säljs bolagets produkter runtom den globala marknaden. Forskning och utveckling främjas via bolagets externa nätverk av forskningsinstitutioner och kliniker. Huvudkontoret ligger i Stockholm.

Kalender

2022-10-21 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-06 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-04 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning BIOG B 3.41 SEK
2021-05-06 Kvartalsrapport 2021-Q1
2021-05-06 Årsstämma 2021
2021-02-04 Bokslutskommuniké 2020
2020-11-25 Extra Bolagsstämma 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-08 Ordinarie utdelning BIOG B 3.75 SEK
2020-05-07 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-06 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-05-09 Ordinarie utdelning BIOG B 4.05 SEK
2019-05-09 Bonusutdelning BIOG B 5.95
2019-02-07 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-08-17 Kvartalsrapport 2018-Q2
2018-04-26 Ordinarie utdelning BIOG B 4.31 SEK
2018-04-26 Bonusutdelning BIOG B 4.69
2018-04-25 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-08 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-04 Ordinarie utdelning BIOG B 3.16 SEK
2017-05-04 Bonusutdelning BIOG B 4.34
2017-05-03 Kvartalsrapport 2017-Q1
2017-05-03 Årsstämma 2017
2017-02-10 Bokslutskommuniké 2016
2016-10-25 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-11 Ordinarie utdelning BIOG B 3.03 SEK
2016-05-11 Bonusutdelning BIOG B 1.97
2016-05-10 Kvartalsrapport 2016-Q1
2016-05-10 Årsstämma 2016
2016-03-18 Extra Bolagsstämma 2016
2016-02-12 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-05-08 Ordinarie utdelning BIOG B 3.46 SEK
2015-05-08 Bonusutdelning BIOG B 1.54
2015-05-07 Årsstämma 2015
2015-05-07 Kvartalsrapport 2015-Q1
2015-02-12 Bokslutskommuniké 2014
2014-10-22 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-05-07 Bonusutdelning BIOG B 3.65
2014-05-07 Ordinarie utdelning BIOG B 3.35 SEK
2014-05-06 Årsstämma 2014
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-12 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-04-29 Ordinarie utdelning BIOG B 4.15 SEK
2013-04-29 Bonusutdelning BIOG B 5.85
2013-04-26 Årsstämma 2013
2013-04-26 Analytiker möte 2013
2013-04-26 Kvartalsrapport 2013-Q1
2013-02-08 Bokslutskommuniké 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-10-23 Analytiker möte 2012
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-09 Bonusutdelning BIOG B 2.74
2012-05-09 Ordinarie utdelning BIOG B 1.26 SEK
2012-05-08 Årsstämma 2012
2012-05-08 Kvartalsrapport 2012-Q1
2012-02-10 Bokslutskommuniké 2011
2011-11-17 Kapitalmarknadsdag 2011
2011-10-25 Kvartalsrapport 2011-Q3
2011-05-11 Bonusutdelning BIOG B 1.08
2011-05-11 Ordinarie utdelning BIOG B 0.92 SEK
2011-05-10 Årsstämma 2011
2011-05-10 Kvartalsrapport 2011-Q1
2011-02-11 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-17 Kvartalsrapport 2010-Q2
2010-05-07 Bonusutdelning BIOG B 0.6
2010-05-07 Ordinarie utdelning BIOG B 0.90 SEK
2010-05-06 Kvartalsrapport 2010-Q1
2010-02-22 Bokslutskommuniké 2009
2009-10-22 Kvartalsrapport 2009-Q3
2009-08-18 Kvartalsrapport 2009-Q2
2009-04-23 Ordinarie utdelning BIOG B 0.40 SEK
2009-04-22 Årsstämma 1
2009-04-22 Kvartalsrapport 2009-Q1
2021-05-06 08:00:00
First quarter 2021
  • Net sales amounted to SEK 202.0 million (182.8), an increase of 10% (excluding foreign exchange effects, 21%). Product sales, net sales excluding royalty revenues, amounted to SEK 196.8 million (177.0), an increase of 11% (excluding foreign exchange effects, 22%).
  • Net sales in the Paediatrics segment reached SEK 161.6 million (142.5), an increase of 13%. Product sales within Paediatrics amounted to SEK 160.0 million (139.3), an increase of 15%.
  • Net sales in the Adult Health segment amounted to SEK 38.7 million (40.2), a decrease of 4%. Product sales within Adult Health amounted to SEK 36.2 million (37.5), a decrease of 4%. 
  • Operating expenses amounted to SEK 81.0 million (77.4), an increase of 5%. Operating expenses included costs for evaluation of acquisition candidates of SEK 2.5 million and costs for restructuring of SEK 7.5 million. Excluding these costs, operating expenses amounted to SEK 71.0 million, a decrease of 9%. 
  • Operating profit increased by 16% to SEK 64.2 million (55.6), which corresponds to an operating margin of 32% (30%).
  • Profit after tax was SEK 50.4 million (41.7), an increase of 21%. 
  • Earnings per share amounted to SEK 2.50 (2.39). No dilutive effects arose.
  • Cash flow amounted to SEK 17.2 million (67.4) and cash and cash equivalents at 31 March 2021 amounted to SEK 1,486.8 million (284.1 at 31 March 2020). 
Key events in the first quarter of 2021
  • On 27 January, BioGaia announced that the products Osfortis and Prodentis have been launched in Sweden and that BioGaia's entire Adult Health portfolio is now available in the domestic market. 
  • On 3 February, BioGaia announced that the Board of Directors of BioGaia has chosen to revise the dividend policy so that 50% (previously 40%) of profit after tax in the Parent Company will be distributed to shareholders.  
  • On 12 February, BioGaia announced that the subsidiary MetaboGen has received approval from the Ethics Committee to start a new clinical study to include people with prediabetes.
  • On 17 March, BioGaia announced that a separate entity, BioGaia Invest, has been established. The focus for BioGaia Invest will be to invest in small companies that promote BioGaia's growth. A total of SEK 150 million has been allocated to enable investments of between SEK 5 and 15 million. 
Key events after the end of the first quarter
  • On 8 April, BioGaia announced that the company has signed an agreement with Minapharm Pharmaceuticals for exclusive rights to sell BioGaia Protectis drops in Egypt.
  • On 13 April, BioGaia announced that a randomised, double-blind, placebo-controlled study in children showed that a supplement of two L. reuteri strains significantly reduced fever and pain in children with upper respiratory tract infections.

CEO's comment

As expected, the pandemic continued to hold the world in its grip in Q1 and will probably continue to do so until a large proportion of the global population has been vaccinated. This situation continues to prevent us from working in the way we and our partners are used to. The increased focus on online sales adopted earlier has now even greater significance and benefits BioGaia, above all in the USA and China. We are therefore giving high priority to increasing our online distribution in several markets and expect that this will further strengthen our sales development even when we can return to more "normal" times.

Following the two first, very strong quarters of 2020, sales decreased in the second half of the year, particularly in some of our more mature markets. It is difficult to predict when the return to more favourable conditions can be expected and it is therefore satisfactory to be able to deliver a sales increase of 10% (an organic growth of 21%) compared to the first quarter of last year. We therefore see a good increase in sales despite the fact that we have lower sales in two large and traditionally strong markets, Finland and Italy. We remain cautious, however, in our assessment of sales growth until the global situation has normalised.

For more information and the entire CEO comment, see attached interim management statement.

 

Teleconference:

Investors, analysts and the media are invited to take part in a teleconference on the interim management statement to be held today 6 May 2021 at 09:30 CET with CEO Isabelle Ducellier and CFO Alexander Kotsinas. To participate in the teleconference, please see Financialhearings.com (https://financialhearings.com/event/13236) for telephone numbers. The teleconference can also be followed here (https://tv.streamfabriken.com/biogaia-q1-2020).  

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the CEO, on 06-05-2021 08:00 CET.